Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $23.67.
Several equities research analysts have weighed in on the stock. Piper Sandler Companies reaffirmed a "buy" rating and issued a $30.00 price target on shares of Acrivon Therapeutics in a research note on Friday, September 6th. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a "neutral" rating to a "buy" rating and set a $16.00 price objective on the stock in a report on Monday, September 16th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday, November 14th. JMP Securities restated a "market outperform" rating and issued a $17.00 price objective on shares of Acrivon Therapeutics in a research note on Monday, September 16th. Finally, BMO Capital Markets lowered their target price on Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a research note on Thursday, November 14th.
Read Our Latest Stock Analysis on ACRV
Institutional Investors Weigh In On Acrivon Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC boosted its holdings in shares of Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company's stock worth $31,093,000 after acquiring an additional 2,353,000 shares during the period. Sands Capital Ventures LLC lifted its holdings in Acrivon Therapeutics by 28.4% during the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company's stock worth $12,311,000 after purchasing an additional 470,000 shares in the last quarter. American International Group Inc. boosted its stake in Acrivon Therapeutics by 39.2% in the 1st quarter. American International Group Inc. now owns 6,016 shares of the company's stock worth $43,000 after purchasing an additional 1,695 shares during the period. Marshall Wace LLP grew its holdings in Acrivon Therapeutics by 58.8% during the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company's stock valued at $5,503,000 after buying an additional 351,397 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Acrivon Therapeutics by 6.6% during the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company's stock valued at $3,626,000 after buying an additional 31,208 shares during the period. 71.62% of the stock is owned by hedge funds and other institutional investors.
Acrivon Therapeutics Trading Up 0.8 %
ACRV stock traded up $0.06 during mid-day trading on Friday, reaching $7.58. The company's stock had a trading volume of 20,198 shares, compared to its average volume of 48,040. The business's 50 day moving average price is $7.51 and its 200 day moving average price is $7.66. The company has a market cap of $236.04 million, a price-to-earnings ratio of -2.81 and a beta of 0.66. Acrivon Therapeutics has a 12 month low of $3.19 and a 12 month high of $11.90.
About Acrivon Therapeutics
(
Get Free ReportAcrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
![Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)](https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=ACRV)
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.